semaglutide during covid reduced mortality in obese patients by lowering infection-related deaths COVID-19 pandemic Weight loss drug Wegovy reduced

The bottom line GLP-1s were first FDA-approved for managing type 2 diabetes and obesity, but research is showing that they might have much wider reaching health benefits

semaglutida (en ingls, semaglutide ) es hoy el agonista del receptor GLP-1 con la base de evidencia cardiovascular ms amplia disponible: desde la reduccin de MACE en diabetes tipo 2 demostrada en SUSTAIN-6 y el reciente ensayo SOUL (semaglutide oral, NEJM 2025), hasta la proteccin cardiovascular en obesidad sin diabetes del ensayo SELECT, pasando por la mejora de sntomas en la insuficiencia cardiaca con FEVI preservada del programa STEP-HFpEF y la nefroproteccin activa en enfermedad renal crnica diabtica del ensayo FLOW

Intravenous (IV) therapy delivers glutathione directly to your bloodstream, for efficient absorption

Ozempic addresses these issues directly by improving insulin sensitivity and reducing glucagon release